157 related articles for article (PubMed ID: 24296403)
1. Investigation of antihypertensive activity of carbopol valsartan transdermal gel containing 1,8-cineole.
Ahad A; Aqil M; Ali A
Int J Biol Macromol; 2014 Mar; 64():144-9. PubMed ID: 24296403
[TBL] [Abstract][Full Text] [Related]
2. Design, formulation and optimization of valsartan transdermal gel containing iso-eucalyptol as novel permeation enhancer: preclinical assessment of pharmacokinetics in Wistar albino rats.
Ahad A; Aqil M; Kohli K; Sultana Y; Mujeeb M
Expert Opin Drug Deliv; 2014 Aug; 11(8):1149-62. PubMed ID: 24830648
[TBL] [Abstract][Full Text] [Related]
3. Formulation and optimization of nanotransfersomes using experimental design technique for accentuated transdermal delivery of valsartan.
Ahad A; Aqil M; Kohli K; Sultana Y; Mujeeb M; Ali A
Nanomedicine; 2012 Feb; 8(2):237-49. PubMed ID: 21704600
[TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic study of eprosartan mesylate-loaded transfersomes Carbopol
Ahad A; Al-Saleh AA; Al-Mohizea AM; Al-Jenoobi FI; Raish M; Yassin AEB; Alam MA
Biomed Pharmacother; 2017 May; 89():177-184. PubMed ID: 28237913
[TBL] [Abstract][Full Text] [Related]
5. Enhanced transdermal delivery of an anti-hypertensive agent via nanoethosomes: statistical optimization, characterization and pharmacokinetic assessment.
Ahad A; Aqil M; Kohli K; Sultana Y; Mujeeb M
Int J Pharm; 2013 Feb; 443(1-2):26-38. PubMed ID: 23313344
[TBL] [Abstract][Full Text] [Related]
6. Transdermal delivery of valsartan: I. Effect of various terpenes.
Rizwan M; Aqil M; Ahad A; Sultana Y; Ali MM
Drug Dev Ind Pharm; 2008 Jun; 34(6):618-26. PubMed ID: 18568912
[TBL] [Abstract][Full Text] [Related]
7. Transdermal delivery enhancement of haloperidol from gel formulations by 1,8-cineole.
Elgorashi AS; Heard CM; Niazy EM; Noureldin OH; Pugh WJ
J Pharm Pharmacol; 2008 Jun; 60(6):689-92. PubMed ID: 18498703
[TBL] [Abstract][Full Text] [Related]
8. Formulation and optimization of lacidipine loaded niosomal gel for transdermal delivery: In-vitro characterization and in-vivo activity.
Qumbar M; Ameeduzzafar ; Imam SS; Ali J; Ahmad J; Ali A
Biomed Pharmacother; 2017 Sep; 93():255-266. PubMed ID: 28738502
[TBL] [Abstract][Full Text] [Related]
9. Design and development of ethosomal transdermal drug delivery system of valsartan with preclinical assessment in Wistar albino rats.
Bhosale SS; Avachat AM
J Liposome Res; 2013 Jun; 23(2):119-25. PubMed ID: 23324030
[TBL] [Abstract][Full Text] [Related]
10. Design, formulation and optimization of novel soft nano-carriers for transdermal olmesartan medoxomil delivery: In vitro characterization and in vivo pharmacokinetic assessment.
Kamran M; Ahad A; Aqil M; Imam SS; Sultana Y; Ali A
Int J Pharm; 2016 May; 505(1-2):147-58. PubMed ID: 27005906
[TBL] [Abstract][Full Text] [Related]
11. Nano vesicular lipid carriers of angiotensin II receptor blocker: Anti-hypertensive and skin toxicity study in focus.
Ahad A; Aqil M; Kohli K; Sultana Y; Mujeeb M
Artif Cells Nanomed Biotechnol; 2016 May; 44(3):1002-7. PubMed ID: 25707444
[TBL] [Abstract][Full Text] [Related]
12. The ameliorated longevity and pharmacokinetics of valsartan released from a gel system of ultradeformable vesicles.
Ahad A; Aqil M; Kohli K; Sultana Y; Mujeeb M
Artif Cells Nanomed Biotechnol; 2016 Sep; 44(6):1457-63. PubMed ID: 25953248
[TBL] [Abstract][Full Text] [Related]
13. Systemic enhancement of papaverine transdermal gel for erectile dysfunction.
Wen MM; El-Kamel AH; Khalil SA
Drug Dev Ind Pharm; 2012 Aug; 38(8):912-22. PubMed ID: 22080854
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 1st communication: antihypertensive effects of valsartan in hypertensive models.
Yamamoto S; Hayashi N; Kometani M; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):604-12. PubMed ID: 9205773
[TBL] [Abstract][Full Text] [Related]
15. QbD-based carbopol transgel formulation: characterization, pharmacokinetic assessment and therapeutic efficacy in diabetes.
Prasad PS; Imam SS; Aqil M; Sultana Y; Ali A
Drug Deliv; 2016; 23(3):1057-66. PubMed ID: 25033041
[TBL] [Abstract][Full Text] [Related]
16. Novel carbopol-based transfersomal gel of 5-fluorouracil for skin cancer treatment: in vitro characterization and in vivo study.
Khan MA; Pandit J; Sultana Y; Sultana S; Ali A; Aqil M; Chauhan M
Drug Deliv; 2015; 22(6):795-802. PubMed ID: 24735246
[TBL] [Abstract][Full Text] [Related]
17. Improved pH-independent dissolution and oral absorption of valsartan via the preparation of solid dispersion.
Park YJ; Lee HK; Im YB; Lee W; Han HK
Arch Pharm Res; 2010 Aug; 33(8):1235-40. PubMed ID: 20803127
[TBL] [Abstract][Full Text] [Related]
18. Role of novel terpenes in transcutaneous permeation of valsartan: effectiveness and mechanism of action.
Ahad A; Aqil M; Kohli K; Sultana Y; Mujeeb M; Ali A
Drug Dev Ind Pharm; 2011 May; 37(5):583-96. PubMed ID: 21469947
[TBL] [Abstract][Full Text] [Related]
19. Enhanced transdermal delivery of ketoprofen from bioadhesive gels.
Singh S; Gajra B; Rawat M; Muthu MS
Pak J Pharm Sci; 2009 Apr; 22(2):193-8. PubMed ID: 19339232
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological profile of valsartan, a non-peptide angiotensin II type 1 receptor antagonist. 2nd communication: valsartan prevents end-organ damage in spontaneously hypertensive stroke-prone rats during 1-year treatment.
Kometani M; Hayashi N; Yamamoto S; Nakao K; Inukai T
Arzneimittelforschung; 1997 May; 47(5):613-9. PubMed ID: 9205774
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
